Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The inspection concluded with zero form 483 observations
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)
Subscribe To Our Newsletter & Stay Updated